NCT06976177View on ClinicalTrials.gov

Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis

PHASE2RecruitingINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

June 7, 2024

Primary Completion Date

August 19, 2025

Study Completion Date

December 12, 2025

Conditions
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Interventions
DRUG

MT1013

MT1013 is a novel calcimimetic agent

Trial Locations (1)

310003

RECRUITING

First Affiliated Hospital College of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

INDUSTRY